Close menu




May 10th, 2021 | 09:14 CEST

CureVac, Cardiol, MorphoSys - Huge sensation in the fight against Corona!

  • Biotechnology
Photo credits: pixabay.com

The biotechnology sector gained tremendous attention since the start of the Corona pandemic. With vaccine makers such as BioNTech or Moderna, investors have achieved returns beyond 1000% since the end of 2019. Currently, drug research against Sars-CoV-2 is in full swing. More effective and safe drugs along with vaccination and testing strategies are critical to managing the pandemic. For investors, this meant a second chance at the next tenbagger.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: NL0015436031 , CA14161Y2006 , DE0006632003

Table of contents:


    Blockbuster potential from Canada
    The biotech sector is on the move as rarely before. In addition to disproportionate share price increases, there have been several takeovers worth billions in recent months. At the beginning of the year, GW Pharmaceuticals sold for USD 7 billion, and recently Roche paid USD 1.8 billion for GenMark Diagnostics. With a stock market value of EUR 57.35 million, the biotechnology Company Cardiol Therapeutics is roughly on the level held by vaccine manufacturers in mid-to-late 2019. At the same time, the multi-product Company from Canada is already a step ahead compared to the BioNTechs and Modernas of the time.

    Promising studies
    Cardiol's research is focused on producing pharmaceutical cannabidiol (CBD) products and the development of innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Approximately 40% of all deaths in Western countries are due to cardiovascular disease. Here, the active ingredient CardiolRx, which can be administered both orally and subcutaneously by the patient, has blockbuster potential. The Phase I study has already been completed without any side effects in the human body.

    The study also showed, among other things, a significant reduction in inflammation and an improvement in endothelial dysfunction. Currently, Cardiol Therapeutics is recruiting 422 patients for a double-blind, placebo-controlled Phase II/III study. 211 patients will be treated with the drug CardiolRx and 211 patients will receive a placebo preparation. The time sequence of observation for each of the primary efficacy aspects will be observed over 28 days. Observations will include overall mortality in both groups, intensive care treatment and use of ventilators, if applicable, cardiac complications such as myocardial infarction, heart failure and stroke.

    Pandemic as a door opener
    The start of the study could help Cardiol Therapeutics make a breakthrough. CardiolRx's anti-inflammatory and cardioprotective properties are being investigated in COVID-19 patients with a high risk of severe cardiovascular complications. Given that possible cases of myocarditis have recently emerged in BioNTech vaccines, industry attention is likely to be increasingly focused on the study results. The capital increase carried out last week shows that the Canadians have slipped into the focus of international investors, as it was oversubscribed several times within a few hours. Due to the high demand, the Company increased the placement from CAD 15 million to CAD 22 million. The issue price was EUR 2.45 per share. Cardiol Therapeutics will use the additional proceeds for further research and clinical development programs and advance them faster. The share is currently trading at EUR 2.18, well below the issue price of the new shares. In addition to the new investors, the analysts at Leede-Jones-Gable are also more than euphoric and see a target price of CAD 12.50 based on the expected sales. From the current price level, this would mean an increase of more than 380%. We see Cardiol Therapeutics as an attractive long-term player in a multi-billion dollar market. However, one should not disregard the risk of investing in biotech companies that are in an early development stage.

    Not much recovery after the shock
    This week was not an easy one for vaccine developers. At the beginning of the week, the overall market was already under pressure due to statements by US Treasury Secretary Janet Yellen. Even more fatal, however, was the announcement by US President Joe Biden. The United States of America joins a group of states demanding that vaccine manufacturers waive their patents to boost vaccine production. The result was a rapid and extremely painful slide in the share price. As a result, the CureVac share price plummeted from EUR 110 to below EUR 75. Compared to industry peers such as BioNTech, who were able to iron out their losses largely, the Tuebingen-based Company remained at a low level. The share price could be boosted by the test results expected for the beginning of June and a possible application for approval of the vaccine. Speculatively, initial positions can be built up at the current level.

    In the red
    The biotech Company MorphoSys moved into the red in the first quarter of 2021. The operating loss was just under EUR 30 million after a profit of EUR 203 million in the previous year. However, at the time, there was a significant one-off payment under a collaboration and licensing agreement with Incyte. Sales also slumped 81% year-on-year to EUR 47.2 million. The net loss per share was EUR 1.27.
    Nevertheless, the Martinsried-based Company confirms its forecast for the year. Group sales are expected to be between EUR 150 million and EUR 200 million. Operating expenses are expected to total between EUR 355 million and EUR 385 million, with 45 to 50% of expenditure going into research and development.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST

    Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?

    • Biotechnology

    Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?

    Read

    Commented by Stefan Feulner on June 27th, 2022 | 12:12 CEST

    BrainChip and Palantir with strong rebound - How does BioNTech react?

    • chips
    • Technology
    • Biotechnology

    The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

    Read

    Commented by Fabian Lorenz on June 23rd, 2022 | 11:35 CEST

    Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

    • Biotechnology
    • Pharma

    Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

    Read